Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05755581
Other study ID # Soh-Med-23-02-16
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date April 1, 2023
Est. completion date August 1, 2025

Study information

Verified date February 2023
Source Sohag University
Contact Amal Ali, MD
Phone 01010454426
Email amal_ali@med.sohag.edu.eg
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Eligible patients will be divided into two groups; one will receive neoadjuvant endocrine therapy and the other one will receive neoadjuvant chemotherapy.


Description:

Patients will be randomized into two groups: The first group (Arm A) will receive NCT; (Any approved Chemotherapy protocol by guidelines. The second group(Arm B) will receive NET; GnRH analog Goserelin acetate 3.6 mg every 4 weeks with tamoxifen 20 mg daily for premenopausal patients or an aromatase inhibitor for postmenopausal patients. - Before and during treatments (every 3 weeks for the NCT group, and every 4 weeks for the NET group), the clinical assessment will be performed for all patients. - All patients will undergo breast magnetic resonance imaging (MRI) before the start of treatment, after 12 weeks (3 months) of treatment, and after the end of treatment before surgery. - We will determine the objective tumor response with every measurement method and assess the response according to the Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. - Treatment will be continued for 19-21 weeks before surgery for the chemotherapy group and 24 weeks for the endocrine therapy group. - Ki-67 will be assessed using a sample of the core biopsy before treatment and a surgery specimen after treatment. - Adverse events will be recorded at every patient visit and will be assessed according to the Common Terminology Criteria for Adverse Events Version 5.0. - Surgery will be performed between the 24th and 26th week. - Arm B Patients who will develop PD or SD after 6 months of treatment will be shifted to arm A. The primary endpoint will be; - The clinical response rate at the end of neoadjuvant treatment, as will be determined using caliper and MRI measurements. - A clinical response included either a complete response (CR), a partial response (PR), Progressive Disease (PD), or Stable Disease (SD) according to the (RECIST) version 1.1. Secondary endpoints will be; - The rate of pathological complete response (pCR). - The rate of breast conservation surgery. - Ki-67 changes. - The length of time to maximum response within a treatment period. - The Adverse events associated with each treatment arm.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date August 1, 2025
Est. primary completion date April 1, 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Any histological type of invasive breast cancer. All grades of breast cancer (I, II, III). ER-positive and/or PR-positive, HER2-negative breast cancer. ER and/or PR level of positivity =34 % (score 4 according to modified Allred score). Clinical Stages: any T N1-3, or T2-4 any N, M0. Exclusion Criteria: - Hormone receptor positivity < 34%. inflammatory breast cancer Metastatic breast cancer. Recurrent breast cancer. Other malignancy. Unfit patients for chemotherapy.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Hormonal Antineoplastics
the Neoadjuvant endocrine therapy group will receive neoadjuvant hormonal therapy.
Chemotherapy drug
the Neoadjuvant chemotherapy group will receive neoadjuvant chemotherapy.

Locations

Country Name City State
Egypt amal Ali Sohag

Sponsors (1)

Lead Sponsor Collaborator
Sohag University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical response rate The primary endpoint will be; The clinical response rate at the end of neoadjuvant treatment, as will be determined using caliper and MRI measurements according to the (RECIST) version 1.1. 6 months
Secondary pathological complete response The rate of pathological complete response after surgery. 6 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02480933 - Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens N/A
Completed NCT05000502 - Exercise, Gut Microbiome, and Breast Cancer: Increasing Reach to Underserved Populations N/A
Not yet recruiting NCT04863833 - Tomosymthesis for Breast Mass Lesion Characterization
Withdrawn NCT06145399 - A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer Early Phase 1
Suspended NCT01320488 - Breast Cancer in Young Women: Is it Different? N/A
Recruiting NCT02089854 - Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer Phase 4
Active, not recruiting NCT01741883 - Side Effect Prevention Training (SEPT) for Nocebo Effects in Breast Cancer Patients N/A
Recruiting NCT06144164 - A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer Phase 3
Recruiting NCT06331793 - Pulsed Electromagnetic Fields for Analgesia Post Mastectomy N/A
Recruiting NCT05439499 - This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer. Phase 3
Terminated NCT03836872 - Acupuncture for Joint Symptoms in Patients With Breast Cancer N/A
Recruiting NCT06332976 - PrefeRences And ChemoTherapy In Breast Cancer patiEnts
Completed NCT01671319 - Dose Dense TC + Pegfilgrastim Support for Breast Cancer Phase 2
Not yet recruiting NCT06092892 - IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases Phase 2
Recruiting NCT05586256 - Ultra-hypofractionated Radiotherapy in Breast Cancer Patients
Not yet recruiting NCT03153631 - Female Sexual Dysfunction in Breast Cancer Patients N/A
Active, not recruiting NCT03059875 - Place of Comprehensive Geriatric Assessment in Patients ≥ 75 Years Care, With Breast Cancer, After Screening With FOG (Oncology Geriatric Filter) N/A
Active, not recruiting NCT02088710 - Expectations and Side Effects of Endocrine Therapy in Women With Breast Cancer N/A
Terminated NCT01083641 - Estrogen for Triple Negative Breast Cancer Phase 2
Recruiting NCT05374161 - An Intervention for Female Breast CANcer: Acceptance and Commitment Therapy (I-CAN-ACT) for Depression and Physical Pain N/A